Short answer
Phathom Pharmaceuticals, Inc. (PHAT) filed its Q1 2026 10-Q quarterly report on Apr 30, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $58M (up 104.4% year over year) with net income of −$30M.
Q1 2026 key financials · XBRL
- Revenue
- $58M
- +104.4% YoY
- Net income
- −$30M
- +67.8% YoY
- Operating margin
- -26.5%
- Gross margin
- 79.4%
- EPS (diluted)
- −$0.37
- +71.8% YoY
Source: XBRL data from the Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 10-Q on SEC EDGAR. USD.
Phathom Pharmaceuticals, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $58.3M, up $29.8M YoY from $28.5M, driven by VOQUEZNA products
- Gross margin 79.4% vs 87.0% YoY, with cost of revenue $12.0M vs $3.7M
- Net loss $30.4M vs $94.3M YoY; operating loss $15.5M vs $78.9M
- Cash and equivalents $180.9M; $175M Hercules term loan advance refinanced existing secured obligations
- Operating profitability expected beginning Q3 2026, excluding stock-based compensation; additional financing may be needed sooner than planned
Risk Factors
- No material changes to risk factors disclosed in the 2025 Form 10-K
- No newly triggered risk factor identified for the quarter ended March 31, 2026
- Updated supply agreement with Sandoz dated March 23, 2026, without corresponding risk-factor changes
- Loan and Security Agreement amended February 25, 2026, without corresponding risk-factor changes
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Phathom Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.